Beijing Geekgene Technology Co., Ltd
Clinical trials sponsored by Beijing Geekgene Technology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental cell therapy takes on advanced cancers Results expected Dec 2026 (estimated)
- Can immune cells from belly fluid fight advanced cancer? Results expected Dec 2026 (estimated)
- New cell injection trial targets tough cancers Results expected Feb 2027 (estimated)
- Experimental T-Cell therapy takes on advanced cancers Results expected Mar 2027 (estimated)
-
Personalized T-Cell therapy takes on advanced lung cancer
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called GK01 for people with advanced lung cancer who have not responded to standard treatments. The therapy uses a patient's own immune cells (T cells) that are specially prepared to attack the cancer. The main goal is to check safe…
Early phase 1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental T-Cell therapy takes on advanced cancers
Disease control Not yet recruitingThis early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …
Early phase 1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental cell therapy takes on advanced cancers
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called GK01 in 15 people with advanced solid tumors that have not responded to standard treatments. GK01 uses a patient's own immune cells, trained to attack their cancer. The main goal is to find a safe dose and check for side effe…
Phase 1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC